Yirong Xiang1, Mengtao Li2, Hui Luo3, Yanhong Wang4, Xinwang Duan5, Cheng Zhao6, Feng Zhan7, Zhenbiao Wu8, Hongbin Li9, Min Yang10, Jian Xu11, Wei Wei12, Lijun Wu13, Hanxiao You1, Junyan Qian1, Xiaoxi Yang1, Can Huang1, Jiuliang Zhao1, Qian Wang1, Xiaomei Leng1, Xinping Tian1, Yan Zhao1, Xiaofeng Zeng14. 1. Department of Rheumatology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China. 2. Department of Rheumatology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China. mengtao.li@cstar.org.cn. 3. Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China. 4. Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, China Academy of Medical Sciences & Peking Union Medical College, Beijing, China. 5. Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. 6. Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. 7. Department of Rheumatology, Hainan General Hospital, Haikou, China. 8. Department of Clinical Immunology and Rheumatology, Xijing Hospital Affiliated to the Fourth Military Medical University, Xi'an, China. 9. Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical College, Hohhot, China. 10. Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China. 11. Department of Rheumatology, First Affiliated Hospital of Kunming Medical University, Kunming, China. 12. Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin, China. 13. Department of Rheumatology, People Hospital of Xinjiang Uygur Autonomous Region, Urumchi, China. 14. Department of Rheumatology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China. zengxfpumc@163.com.
Abstract
BACKGROUND: Scarring alopecia in systemic lupus erythematosus (SLE) patients caused reduced life quality and prolonged disease course. This case-control study aims to survey the prevalence of scarring alopecia during the disease course of SLE and evaluate the risk factors for scarring alopecia in Chinese SLE patients. METHODS: SLE patients in Chinese SLE treatment and Research group (CSTAR) were recruited. Scarring alopecia was defined according to SLICC/ACR-DI which was collected during follow-up visits or via self-reported questionnaires. We collected demographic characteristics, common comorbidities, autoantibody profiles, disease activity status, major organ involvements, and treatment strategies of these patients at registry. Univariate and multivariate logistic regression analyses were used to investigate the risk factors for scarring alopecia. RESULTS: We recruited 4792 SLE patients, and 374 (7.80%) patients had scarring alopecia. Mucocutaneous lesions (OR 2.062, p < 0.001), high SLICC/ACR-DI (OR 1.409, p < 0.001), and positive anti-Sm (OR 1.374, p = 0.029) were risk factors for scarring alopecia, while renal (OR 0.714, p = 0.028) and cardio-respiratory involvements (OR 0.347, p = 0.044), and immunosuppressant treatment (OR 0.675, p < 0.001) were significantly negative associated with it. CONCLUSIONS: The prevalence of scarring alopecia in SLE patients is 7.80%. Active treatment strategies should be adopted to prevent scarring alopecia occurring.
BACKGROUND: Scarring alopecia in systemic lupus erythematosus (SLE) patients caused reduced life quality and prolonged disease course. This case-control study aims to survey the prevalence of scarring alopecia during the disease course of SLE and evaluate the risk factors for scarring alopecia in Chinese SLEpatients. METHODS:SLEpatients in Chinese SLE treatment and Research group (CSTAR) were recruited. Scarring alopecia was defined according to SLICC/ACR-DI which was collected during follow-up visits or via self-reported questionnaires. We collected demographic characteristics, common comorbidities, autoantibody profiles, disease activity status, major organ involvements, and treatment strategies of these patients at registry. Univariate and multivariate logistic regression analyses were used to investigate the risk factors for scarring alopecia. RESULTS: We recruited 4792 SLEpatients, and 374 (7.80%) patients had scarring alopecia. Mucocutaneous lesions (OR 2.062, p < 0.001), high SLICC/ACR-DI (OR 1.409, p < 0.001), and positive anti-Sm (OR 1.374, p = 0.029) were risk factors for scarring alopecia, while renal (OR 0.714, p = 0.028) and cardio-respiratory involvements (OR 0.347, p = 0.044), and immunosuppressant treatment (OR 0.675, p < 0.001) were significantly negative associated with it. CONCLUSIONS: The prevalence of scarring alopecia in SLEpatients is 7.80%. Active treatment strategies should be adopted to prevent scarring alopecia occurring.
Authors: Sung Soo Ahn; Seung Min Jung; Juyoung Yoo; Sang-Won Lee; Jason Jungsik Song; Yong-Beom Park Journal: Rheumatol Int Date: 2019-09-24 Impact factor: 2.631
Authors: George Bertsias; Dimitrios T Boumpas; Antonis Fanouriakis; Myrto Kostopoulou; Alessia Alunno; Martin Aringer; Ingeborg Bajema; John N Boletis; Ricard Cervera; Andrea Doria; Caroline Gordon; Marcello Govoni; Frédéric Houssiau; David Jayne; Marios Kouloumas; Annegret Kuhn; Janni L Larsen; Kirsten Lerstrøm; Gabriella Moroni; Marta Mosca; Matthias Schneider; Josef S Smolen; Elisabet Svenungsson; Vladimir Tesar; Angela Tincani; Anne Troldborg; Ronald van Vollenhoven; Jörg Wenzel Journal: Ann Rheum Dis Date: 2019-03-29 Impact factor: 19.103
Authors: Joseph F Merola; Stephen D Prystowsky; Christina Iversen; Jose A Gomez-Puerta; Tabatha Norton; Peter Tsao; Elena Massarotti; Peter Schur; Bonnie Bermas; Karen H Costenbader Journal: J Am Acad Dermatol Date: 2013-03-28 Impact factor: 11.527
Authors: Evan W Piette; Kristen P Foering; Aileen Y Chang; Joyce Okawa; Thomas R Ten Have; Rui Feng; Victoria P Werth Journal: Arch Dermatol Date: 2011-11-21